Theorem Clinical Research
Theorem Clinical Research Inc. is a leading midsized provider of comprehensive clinical research and development services with offices in more than 30 countries and a customer base comprised of some of the world’s leading pharmaceutical, biotech and medical device companies.
This is a FREE LISTING on PMHUB
Below are full profiles from other companies in related areas
Havas Life London
We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by strategically aligning promotion, medical education and PR across the product…
Advertising, Branding, Clinical Research, Conference/meetings/events, Creative and design, Digital communications, Management consultancies, Market access, Market research, Marketing consultancies, Medical communications, Medical education, Patient support and adherence, Public relations, Regulatory affairs
Sciterion
Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make a positive contribution to patient care. Real world experience of…
Streaming Well
Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual stories and interactive experiences that connect with people.
Uniphar
Uniphar Group is a trusted global partner to pharmaceutical, medtech, and supply chain and retail companies, working to improve patient access to medicines around the world.
Company Details
Latest Content from PMHub
What have you learned about your customers recently?
White Papers and Resources | July 6, 2016 | Anthill Agency
Your customer-facing staff continually gets told about the needs and wants of your customers. Are you learning what they are learning?
Infographic: HIV Market Snapshot
White Papers and Resources | July 6, 2016 | Inizio
Our latest HIV infographic, taken from data collected from syndicated tracking study Therapy Watch, reveals that more than 3 in 5 naive or switch patients are currently treated with a STR (single...
Infographic: The vaccine opportunity in Asia
White Papers and Resources | July 6, 2016 | Inizio
As predicted, the vaccine market in emerging and developing countries has continued to expand. While the global vaccine market is expected to grow at around 12% annually over the next...
Webinar: What next for biosimilars?
White Papers and Resources | July 6, 2016 | Inizio
Tuesday 19th July 15:00 BST/10:00 EDT/16:00 CEST
Understanding the Patient Journey
White Papers and Resources | July 6, 2016 | Inizio
The patient journey is changing. Patients are now much more educated and engaged. They have access to information and want to be involved in decisions around their treatment programme. Technology...
Case Study: Oncology diagnostic biomarker landscaping study
White Papers and Resources | July 6, 2016 | Inizio
The challenge:Our client needed to understand moleculardiagnostic testing growth opportunities for a new biomarker in oncology. They wanted to understand the current market landscape, identify potential leverage points that would maximise use of the biomarker...
Research Partnership publishes 2016 Living with RA reports
White Papers and Resources | July 6, 2016 | Inizio
Research Partnership has published new Living with rheumatoid arthritis (RA) EU and US market reports for 2016.
Article: The Art of Storytelling in Pharma Market Research
White Papers and Resources | July 6, 2016 | Inizio
Published in PBIRG Perspective, May 2016, vol. 18 No.1, By Julie Denny, Marketing Director
Video: Immuno-oncology therapies
White Papers and Resources | July 6, 2016 | Inizio
Immuno-oncology therapies which harness the body’s own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment. However, these therapies come with a very high price...
The challenges of conducting effective pharmaceutical market research in emerging markets
White Papers and Resources | July 6, 2016 | Inizio
Published in Quirk's Marketing Research Review, April 2016, By Marc Yates, Director of Emerging Markets